Donald Picker
Founder at MOLECULIN BIOTECH, INC.
Net worth: 56 004 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Walter Klemp | M | 64 |
Moleculin LLC
 Moleculin LLC Pharmaceuticals: MajorHealth Technology Moleculin LLC develops dermatological products for treatment of skin disorders. The company was founded by Klemp V. Walter in 2006 and is headquartered in Houston, TX. | 18 years |
| John Climaco | M | 55 | 7 years | |
| James Leonard Ivins | M | 84 |
Secure Voice Communications, Inc.
 Secure Voice Communications, Inc. Internet Software/ServicesTechnology Services Part of Breitling Energy Corp., Secure Voice Communications, Inc. develops VoIP technologies. The private company is based in Plant City, FL. James Leonard Ivins has been the CEO of the company since 2007. Secure Voice Communications was acquired by Edgeline Holdings, Inc. from eLinear, Inc. on July 25, 2007 for $3,239.92 million.
Edgeline Holdings, Inc.
| 17 years |
| Jerzy Gumulka | M | 74 |
Moleculin LLC
Moleculin LLC Pharmaceuticals: MajorHealth Technology Moleculin LLC develops dermatological products for treatment of skin disorders. The company was founded by Klemp V. Walter in 2006 and is headquartered in Houston, TX. | 14 years |
| Bettina Cockroft | M | 57 | 1 years | |
| Robert George | M | 74 | 9 years | |
| Sandra Silberman | M | 69 | 7 years | |
| Jeffry Keyes | M | 51 | 6 years | |
| Elizabeth Cermak | F | 66 | 4 years | |
| Faith Charles | F | 62 | 1 years | |
| Howard C. Chandler | M | 62 |
Sinapis Pharma, Inc.
 Sinapis Pharma, Inc. BiotechnologyHealth Technology Sinapis Pharma, Inc. provides biotechnology services. It develops methamphetamine, a low-dose intravenous infusion. The company was founded by Howard C. Chandler and Peter Von Doersten in 2009 and is headquartered in Jacksonville, FL. | 15 years |
| Michael Cannon | M | 78 | 9 years | |
| Amy Mahery | F | 47 | - | |
| Jonathan Foster | M | 60 | 8 years | |
| Albert Henry | M | - |
Sinapis Pharma, Inc.
Sinapis Pharma, Inc. BiotechnologyHealth Technology Sinapis Pharma, Inc. provides biotechnology services. It develops methamphetamine, a low-dose intravenous infusion. The company was founded by Howard C. Chandler and Peter Von Doersten in 2009 and is headquartered in Jacksonville, FL. | 18 years |
| John Paul Waymack | M | 71 | - | |
| Christopher Downs | M | 45 | 5 years | |
| Joy Yan | M | 44 | 2 years | |
| Dennis McNamara | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Gary Jacob | M | 77 |
Callisto Pharmaceuticals, Inc.
 Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 10 years |
| Craig C. Talluto | M | - |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 8 years |
| Bernard Denoyer | M | 77 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 9 years |
| Judson A. Cooper | M | 65 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | - |
| Carl Evans | M | 77 | 6 years | |
| John Brancaccio | M | 76 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 9 years |
| Andrzej Andraczke | M | 81 | 6 years | |
| Matthew Lourie | M | 43 | 2 years | |
| Joshua D. Schein | M | 63 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | - |
| Randall K. Johnson | M | 77 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 8 years |
| Jacqueline Northcut | F | 62 | 2 years | |
| David Lichtenstein | M | - |
State University of New York at Albany
| 4 years |
| Andrew M. Baker | M | 68 |
State University of New York at Albany
| 4 years |
| Waldemar Priebe | M | - | - | |
| George Humbert Keith | M | - |
State University of New York at Albany
| 4 years |
| Steven J. Balog | M | 69 |
State University of New York at Albany
| 4 years |
| Robert C. Shepard | M | - |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 7 years |
| Frank di Genova | M | - |
State University of New York at Albany
| 4 years |
| Joel E. Breiter | M | - |
State University of New York at Albany
| 4 years |
| Alan H. Solarz | M | - |
State University of New York at Albany
| 4 years |
| Steve M. Mekler | M | - |
State University of New York at Albany
| 4 years |
| Doug Bauer | M | - |
State University of New York at Albany
| 4 years |
| Edward J. Arcuri | M | 73 |
State University of New York at Albany
| 4 years |
| Michael Klein | M | 69 |
State University of New York at Albany
| 4 years |
| Christopher Aidun | M | - |
State University of New York at Albany
| 4 years |
| Michael J. Cramer | M | 72 |
State University of New York at Albany
| 4 years |
| Bruce W. Fiedler | M | 59 |
Tapestry Pharmaceuticals, Inc.
 Tapestry Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tapestry Pharmaceuticals, Inc. develops, manufactures, and markets an anti-cancer pharmaceutical called Paclitaxel. It focuses on the development of proprietary therapies for the treatment of cancer, new products and technologies may involve the examination of individual molecules and classes of compounds. The company was founded in 1991 and is headquartered in Ankeny, IA. | - |
| Maureen Helmer | F | 67 |
State University of New York at Albany
| 4 years |
| Matthew Majoros | M | - |
Tapestry Pharmaceuticals, Inc.
Tapestry Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tapestry Pharmaceuticals, Inc. develops, manufactures, and markets an anti-cancer pharmaceutical called Paclitaxel. It focuses on the development of proprietary therapies for the treatment of cancer, new products and technologies may involve the examination of individual molecules and classes of compounds. The company was founded in 1991 and is headquartered in Ankeny, IA. | 2 years |
| Pamela A. Harris | M | - |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | - |
| Riccardo Dalla-Favera | M | 72 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 6 years |
| William E. Kelly | M | 74 |
State University of New York at Albany
| 4 years |
| John Robert LaPann | M | - |
State University of New York at Albany
| 1 years |
| Gabriele Cerrone | M | 52 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 10 years |
| Kunwar Shailubhai | M | 67 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 3 years |
| Louis Ploth | M | 70 | 1 years | |
| Iain Ross | M | 71 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | - |
| Carl A. Chase | M | 73 |
Edgeline Holdings, Inc.
| 1 years |
| David F. Holstein | M | - |
State University of New York at Albany
| 4 years |
| David H. Waterman | M | - |
State University of New York at Albany
| 4 years |
| Christoph Bruening | M | 56 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 7 years |
| Steven M. Plumb | M | 64 |
Edgeline Holdings, Inc.
| - |
| Stephen K. Carter | M | 85 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 4 years |
| Mark Perlson | M | - |
State University of New York at Albany
| 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 63 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Donald Picker
- Personal Network